Multiple myeloma: Microstructural analysis of lumbar trabecular bones in patients without visible bone lesions - Preliminary results

Radiology

Volumn 260, Issue 2, 2011, Pages 472-479

  Takasu, Miyuki ^a   Tani, Chihiro ^a   Ishikawa, Miho ^a   Date, Shuji ^a   Horiguchi, Jun ^a   Kiguchi, Masao ^a   Tamura, Akihisa ^c   Sakai, Akira ^b   Asaoku, Hideki ^c   Nango, Nobuhito ^d   Awai, Kazuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d Ratoc System Engineering   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BONE LESION; BONE STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; IMAGE ANALYSIS; LUMBAR SPINE; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; SPINE FRACTURE; STRUCTURE ANALYSIS; THICKNESS; TRABECULAR BONE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LINEAR MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SPINAL FRACTURES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960668755     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11101746     Document Type: Article

References (43)

1. Durie BG. Staging and kinetics of multiple myeloma. Clin Haematol 1982;11(1):3-18.
2. Nau KC, Lewis WD. Multiple myeloma: diagnosis and treatment. Am Fam Physician 2008;78(7):853-859.
3. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50(2):95-102. (Pubitemid 23061274)
4. Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. Br J Cancer 1996;73(9):1101-1107. (Pubitemid 26131232)
5. Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000;82(7):1254-1260. (Pubitemid 30145341)
6. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17(4):775-779. (Pubitemid 36519375)
7. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21(1):16-19.
8. Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008;190(4):1097-1104. (Pubitemid 351571514)
9. Baur A, Bartl R, Pellengahr C, Baltin V, Reiser M. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer 2004;101(11):2599-2604. (Pubitemid 39532290)
10. Lecouvet FE, Malghem J, Michaux L, et al. Vertebral compression fractures in multiple myeloma. II. Assessment of fracture risk with MR imaging of spinal bone marrow. Radiology 1997;204(1):201-205.
11. Durie BGM. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006;42(11):1539-1543. (Pubitemid 44137426)
12. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr 2007;31(3):342-347. (Pubitemid 46849898)
13. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842-854.
14. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semi-quantitative technique. J Bone Miner Res 1993;8(9):1137-1148. (Pubitemid 23261108)
15. Friedman JH. Regularized discriminant analysis . J Am Stat Assoc 1989;84(405):165-175.
16. Hildebrand T, Ruegsegger P. A new method for the model-independent assessment of thickness in three dimensional images. J Microsc 1997;185(1):67-75. (Pubitemid 27060526)
17. Fazzalari NL, Parkinson IH. Fractal dimension and architecture of trabecular bone. J Pathol 1996;178(1):100-105. (Pubitemid 26052088)
18. Odgaard A, Gundersen HJ. Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 1993;14(2):173-182. (Pubitemid 23098966)
19. Kaiser HF. The varimax criterion for analytic rotation in factor analysis. Psychometrika 1958;23(3):187-200.
20. Harrigan TP, Mann RW. Characterization of microstructural anisotropy in orthotropic materials using a second rank tensor. J Mater Sci 1984;19(3):761-767.
21. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412-3420.
22. Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med 1985;145(8):1451-1452. (Pubitemid 15049802)
23. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290(24):3199-3206. (Pubitemid 38020681)
24. Modic MT, Obuchowski N. Whole-body CT screening for cancer and coronary disease: does it pass the test? Cleve Clin J Med 2004;71(1):47-56. (Pubitemid 39220368)
25. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43(11):1457-1463.
26. Dinter DJ, Neff WK, Klaus J, et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol 2009;88(5):457-464.
27. Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone microstructure with age and gender. Osteoporos Int 2008;19(10):1473-1483.
28. Riggs BL, Melton LJ 3rd, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004;19(12):1945-1954. (Pubitemid 41103408)
29. Ito M, Ikeda K, Nishiguchi M, et al. Multidetector row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res 2005;20(10):1828-1836. (Pubitemid 41361884)
30. Major NM, Helms CA, Richardson WJ. The "mini brain": plasmacytoma in a vertebral body on MR imaging. AJR Am J Roentgenol 2000;175(1):261-263. (Pubitemid 30415575)
31. Galieni P, Cavo M, Avvisati G, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol 1995;6(7):687-691.
32. Cervoni L, Celli P, Salvati M, Tarantino R, Fortuna A. Solitary plasmacytoma of the spine: relationship of IGM to tumour progression and recurrence. Acta Neurochir (Wien) 1995;135(3-4):122-125.
33. Chak LY, Cox RS, Bostwick DG, Hoppe RT. Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol 1987;5(11):1811-1815. (Pubitemid 18020847)
34. Bataille R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 1990;76(4):484-487.
35. Ehara S. "Mini brain" of plasmacytoma [letter]. AJR Am J Roentgenol 2001;176(4):1076.
36. Baur A, Stäbler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95(6):1334-1345.
37. Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol 1997;99(3):649-655. (Pubitemid 27519869)
38. Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999;104(4):723-729. (Pubitemid 29143489)
39. Walker R, Jones-Jackson L, Rasmussen E, et al. Diagnostic imaging of multiple myeloma: FDG PET and MRI complementary for tracking short vs long term tumour response [abstr]. Blood 2004;104(11):758.
40. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24(5):1043-1049.
41. Henry MJ, Pasco JA, Seeman E, Nicholson GC, Sanders KM, Kotowicz MA. Fracture thresholds revisited. Geelong Osteoporosis Study. J Clin Epidemiol 2002;55(7):642-646. (Pubitemid 34831056)
42. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164(10):1108-1112. (Pubitemid 38668990)
43. Seeman E. From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 1997;12(4):509-521. (Pubitemid 27155210)